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Background 
In 2012, the Joint Committee on Vaccination and Immunisation (JCVI) 
recommended that the routine annual influenza vaccination programme 
should be extended to include children, both to provide individual protection to 
the children themselves and to reduce transmission across all age groups to  
lessen levels of flu overall and reduce the burden of flu across the population.  
 
The phased introduction of this extension began in 2013 when flu vaccine 
was offered to all two and three year old children and to those aged four to 
ten years (up to and including pupils in school year 6) in seven different 
geographical pilot areas. Each year, more age groups have been added to 
the national programme and the pilots in primary school aged children started 
in 2013/14 have continued. 
 
In the 2019/20 flu season, flu vaccine should be offered to all children who 
are aged two to ten years old (but not eleven years or older) on 31 August 
2019. This means all primary school-aged children are now eligible for 
vaccination. Flu vaccine should also be offered to children from six months of 
age in clinical risk groups. 
 
The key change to the childhood flu programme in the 2019/20 flu season is 
that: 
• Children in School Year 6 (children aged 10-11 years) will be included 
in the programme this year  
 
 
Extension of the flu vaccination programme to include healthy children  
Extending the flu vaccination programme to include healthy children aims to 
lower the public health impact of flu by:  
 
• providing direct protection to children, helping to prevent a large 
number of cases of flu in children 
• providing indirect protection by lowering flu transmission from children 
to other children, adults and to those in the clinical risk groups of any 
age and averting cases of severe flu and flu-related deaths in older 
adults and people with clinical risk factors 
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Studies commissioned by JCVI1 suggested that, despite the high cost, 
extending the flu vaccination programme to all children is highly likely to be 
cost-effective and well below the established cost-effectiveness threshold 
when indirect protection to the whole population is taken into account, 
particularly over the longer term.  
 
The role of healthcare professionals 
Healthcare professionals have a key role in promoting high uptake of flu 
vaccination in children through: 
 
• understanding the benefits and evidence base relating to the use of the 
vaccine against flu 
• promoting the vaccine to parents/carers of children who are eligible to 
receive the flu vaccination  
• safely administering flu vaccines in accordance with the vaccine 
schedule 
• ensuring any adverse effects are managed and reported appropriately 
  
                                            
 
1 Pitman RJ, Nagy LD and Sculpher MJ (2013) Cost-effectiveness of childhood influenza vaccination in England 
and Wales: Results from a dynamic transmission model. Vaccine 31(6): 927-42. 
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Influenza 
Flu is a highly infectious, acute, viral infection of the respiratory tract. It is 
transmitted by the inhalation of infected droplets and aerosols and by hand-
to-mouth/eye contamination from an infected surface. The incubation period 
can be one to five days (average two to three days). 
 
There are three types of influenza virus which affect humans. Influenza A 
causes epidemics and pandemics. This virus is found in many different 
animals and may spread between them. Birds, particularly wildfowl, are the 
main animal reservoir. The A viruses can live and multiply in wildfowl from 
where they can transmit to humans. Influenza B tends to cause less severe 
disease and smaller outbreaks. It is predominantly found in humans and the 
burden of disease is mostly in children. Influenza C causes minor respiratory 
illness only. 
 
Groups affected by flu  
Flu can affect anyone, but it is a more serious illness in babies, pregnant 
women, older people and those with certain underlying conditions. 
 
Symptoms of flu 
In healthy individuals, flu is usually an unpleasant but self-limiting illness with 
recovery in five to seven days. Common symptoms include the sudden onset 
of fever, chills, headache, myalgia (muscle aches) and severe fatigue. 
Sufferers can also experience a dry cough, sore throat and stuffy nose. In 
young children, gastrointestinal symptoms such as vomiting and diarrhoea 
may be seen. 
 
Possible complications of flu 
Common complications may include bronchitis, otitis media (middle ear 
infection) in children and sinusitis. Other less common complications include 
secondary bacterial pneumonia, viral pneumonia, meningitis and encephalitis.  
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Flu vaccination programme for children 
Live attenuated influenza vaccine (LAIV) 
The flu vaccine that should be offered to most children in the eligible cohort 
groups is a live attenuated influenza intranasal vaccine (LAIV). It contains an 
attenuated (weakened) vaccine virus that is also cold adapted so that it 
cannot cause the disease that it protects against. 
 
LAIV is manufactured by AstraZeneca/MedImmune and has been sold in 
many countries for 16 years. Only one LAIV vaccine is available, marketed as 
Fluenz Tetra for the UK and EU market, and FluMist Quadrivalent for the US 
market. Fluenz Tetra and FluMist Quadrivalent are the same product in 
different packaging.  
 
LAIV may not be suitable for all children who are eligible for the flu vaccine 
(please refer to contraindications section below). For those children in whom 
LAIV is contraindicated, a suitable injectable inactivated influenza vaccine 
should be offered instead. 
 
Presentation of LAIV 
LAIV is supplied in a box containing 10 single-use, prefilled nasal applicators. 
Each applicator contains 0.2ml nasal suspension. The nasal applicator is 
ready to use - no reconstitution or dilution is required. The nasal suspension 
is colourless to pale yellow, clear to opalescent. Small white particles may be 
present. 
 
Cold adapted influenza virus 
A cold adapted virus is designed not to reproduce well at body temperature 
(37°C). So it will not replicate in the lungs but will reproduce at the cooler 
temperatures found in the nose (nasal mucosa). This allows the child to 
produce antibodies, which then protect against infection. These antibodies 
work in the lining of the airways and are not produced in response to the 
inactivated flu vaccine. By limiting viral reproduction to the nose, the worst 
symptoms of flu are avoided. 
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Transmission of vaccine virus in LAIV 
There is a theoretical potential risk of transmission of the live attenuated flu 
virus in LAIV to very severely immunosuppressed contacts (for example bone 
marrow transplant patients requiring isolation) for one to two weeks following 
vaccination. In the US, where there has been extensive use of LAIV, there 
have been no reported instances of illness or infections from the vaccine virus 
among immunocompromised patients inadvertently exposed. Where close 
contact with very severely immunosuppressed contacts (for example 
household members) is likely or unavoidable however, consideration should 
be given to using an appropriate inactivated flu vaccine instead.  
 
Healthcare workers and school staff may be asked questions in relation to the 
safety of the LAIV being given in schools. Specific information on potential 
exposure during administration, and from recently vaccinated children, is 
outlined below.  
 
The nasal influenza vaccine uses a live attenuated (weakened) influenza 
virus which helps protect against influenza infection in those who receive it. 
LAIV does not cause clinical influenza in those immunised and is offered to 
children because it provides good overall protection for children against 
influenza virus and is expected to provide some cross-protection against 
mismatched strains. It has a good safety record and is easier to administer 
than injected vaccines. Millions of doses of LAIV have been given in the USA 
and in Canada. This vaccine is also given to children in Finland. In the UK, 
millions of doses of LAIV have been given to young children and to school 
age children during the last six flu seasons. A small number of respiratory 
illnesses (including wheeze) were reported in the contacts of vaccinated 
children. Most of these events were self-limiting and some of them are likely 
to have been coincidental. 
  
LAIV has a good safety record and unvaccinated contacts are not at risk of 
becoming seriously ill with the flu vaccine virus, either through being in the 
same room where flu vaccine has been given or by being in contact with a 
recently vaccinated individual. Excluding children from school during the 
period when LAIV is being offered or in the following weeks is therefore not 
considered necessary. The only exception to this would be the tiny number of 
children who are extremely immunocompromised (for example those who 
have just had a bone marrow transplant). These children are normally 
advised not to attend school anyway because of the definite and much higher 
risk of being in contact with other infections, including ‘wild’ influenza, that 
spread in schools.  
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Exposure to vaccine virus during administration 
 
• Administration of the vaccine is via a nasal applicator which delivers 
just 0.1ml (around 1/50th of a teaspoon) of fluid into each nostril. There 
is not a ‘mist’ of vaccine virus in the air when children are being 
vaccinated and therefore others in the room should not be at risk of 
“catching” the vaccine virus. The room or school in which 
administration of nasal influenza vaccine has taken place does not 
require any special cleaning afterwards. 
 
• Images of the vaccine being squirted into the air (which are widely 
available on the internet) and the US name of the vaccine (FluMist® 
Quadrivalent) may give a false impression that a vaccine mist fills the 
room. These images are intended to show how gently the vaccine 
comes out when inserted into the nose but the vaccine does not create 
an external mist – almost all the fluid is immediately absorbed into the 
child’s nose where it has been sprayed. 
 
• Healthcare workers administering LAIV may, theoretically, be exposed 
to the vaccine virus if it is accidentally released outside of the child’s 
nose. In the US, where there has been extensive use of the vaccine 
over many years, transmission of the vaccine virus to healthcare 
workers has not been reported to date. Health care workers who are 
immunocompromised and those who are pregnant can safely 
administer the vaccine. As a precautionary measure, however, very 
severely immunocompromised healthcare workers should not 
administer LAIV.  
 
Shedding of vaccine virus 
 
• Although vaccinated children are known to shed virus a few days after 
vaccination, it is less able to spread from person to person than the 
natural infection. The amount of virus shed is normally below the levels 
needed to pass on infection to others and the virus does not survive for 
long outside of the body. This is in contrast to natural flu infection, 
which spreads easily during the flu season. In schools where LAIV is 
administered therefore, the overall risk of contact with influenza viruses 
is massively reduced by having a large number of children vaccinated, 
thus reducing their risk of wild flu infection.  
 
• In the US, where there has been extensive use of LAIV for many 
years, serious illness amongst immunocompromised contacts who are 
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inadvertently exposed to vaccine virus has never been observed. 
Expert doctors at Great Ormond Street Hospital, who deal with many 
children with very serious immune problems, do not recommend 
keeping such children off school purely because of LAIV vaccination.  
 
• A tiny number of children who are extremely severely 
immunocompromised e.g. immediately after a bone marrow transplant, 
would not be attending school anyway because the risk from all the 
other infections that children pass to each other at school would be too 
great. It is important that all children with immune problems should 
themselves be vaccinated, usually with an injected inactivated vaccine. 
Similarly, healthy children who have family contacts who are very 
severely immunocompromised should be given an inactivated 
influenza vaccine. 
 
Vaccine recommendations 
In England, flu vaccine should be offered to all children who are aged two to 
ten years old (but not eleven years or older) on 31 August 2019 and to 
children aged from 2 years up to 18 years in clinical risk groups. LAIV should 
be offered unless contraindicated (please refer to contraindications section 
below). For further information about the childhood flu immunisation 
programme 2019/20, please refer to the annual flu letter from 
DHSC/PHE/NHS England: The national flu immunisation programme 
2019/20. 
 
Number of vaccine doses required 
Children NOT in clinical risk groups only require one dose of LAIV. A single 
dose is 0.2ml (administered as 0.1ml per nostril). 
 
The marketing authorisation holder’s Summary of Product Characteristics2 
(SPC) states that, for children who have not previously been vaccinated 
against seasonal flu, a second dose should be given after an interval of at 
least four weeks. The JCVI has considered this issue and has recommended 
that as a second dose of the vaccine provides only modest additional 
protection, children who are not in a clinical risk group should be offered a 
single dose of LAIV. 
 
Healthcare professionals are reminded that in some circumstances, the 
recommendations regarding vaccines given in the Green Book chapters may 
                                            
 
2 Fluenz Tetra Summary of Product Characteristics (SPC). Available at: www.medicines.org.uk/emc/product/3296     
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differ from those in the SPC for a particular vaccine. When this occurs, the 
recommendations in the Green Book are based on current expert advice 
received from the JCVI and this advice should be followed. The Green Book 
recommendations and/or further advice from the Department of Health and 
Social Care/Public Health England should be reflected in PGDs.  
 
Children aged two years to less than nine years who are in a clinical risk 
group and who have not received flu vaccine before should receive two doses 
of LAIV. The second dose should be given at least four weeks after the first.  
 
Administering an inactivated influenza vaccine after a first dose of LAIV 
In the event that eligible children who have previously received one dose of 
LAIV require a second dose (ie those in clinical risk groups who have never 
received flu vaccine before and are aged between two and less than nine 
years) but all LAIV stock has expired, a suitable inactivated injectable flu 
vaccine should be offered as an alternative, allowing a four-week minimum 
interval period between the two doses.  
 
Contraindications and precautions 
There are very few children who cannot receive any flu vaccine. When there 
is doubt, appropriate advice should be sought promptly from the local NHS 
England Screening and Immunisation team, local Health Protection team or a 
consultant paediatrician to minimise the period the child is left unvaccinated. 
 
Contraindications 
 
LAIV should not be given to a child or adolescent who: 
 
• is under 24 months or 18 years or older 
• has had a confirmed anaphylactic reaction to a previous dose of flu vaccine 
• has had a confirmed anaphylactic reaction to any component of the vaccine 
• is clinically severely immunodeficient due to conditions or 
immunosuppressive therapy such as: acute and chronic leukaemias; 
lymphoma; HIV infection not on highly active antiretroviral therapy 
(HAART); cellular immune deficiencies; and high dose corticosteroids 
(prednisolone at least 2mg/kg/day for a week or 1mg/kg/day for a 
month or equivalent) 
• is receiving salicylate therapy 
• is pregnant  
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The Green Book3 chapter on ‘contraindications and special considerations’ 
(chapter 6) gives further advice on the use of live vaccines in individuals who 
are severely immunosuppressed. Where LAIV is contraindicated, 
consideration should be given to the use of inactivated flu vaccine instead. 
 
LAIV is not contraindicated for use in children or adolescents with stable HIV 
infection receiving antiretroviral therapy; those receiving topical steroids, 
standard dose inhaled corticosteroids, low-dose systemic corticosteroids or 
those receiving corticosteroids as replacement therapy, for example for 
adrenal insufficiency.  
 
Precautions 
LAIV is not recommended for children and adolescents currently experiencing 
an acute exacerbation of symptoms including those who have had increased 
wheezing and/or needed additional bronchodilator treatment in the previous 
72 hours. Such children should be offered a suitable inactivated influenza 
vaccine to avoid a delay in protection. 
 
There are limited safety data in children who require regular oral steroids for 
maintenance of asthma control, or have previously required intensive care for 
asthma exacerbation – such children should only be given LAIV on the advice 
of their specialist. As these children may be at higher risk from influenza 
infection, those who cannot receive LAIV should receive a suitable inactivated 
influenza vaccine.  
 
If a child is acutely unwell, immunisation may be postponed until they have 
fully recovered. This is to avoid confusing the differential diagnosis of any 
acute illness by wrongly attributing any signs or symptoms to any adverse 
effects of the vaccine. However, minor illnesses without fever or systemic 
upset are not valid reasons to postpone immunisation. 
 
Reporting adverse reactions 
As with all vaccines and other medicines, healthcare professionals and 
patients are encouraged to report suspected adverse reactions to flu vaccines 
using the yellow card reporting scheme at http://mhra.gov.uk/yellowcard. The 
inactivated quadrivalent flu vaccine available for children who cannot receive 
LAIV carries a black triangle symbol (▼). This symbol is used as a reminder 
to healthcare professionals and the public to report all suspected side-effects 
                                            
 
3 Public Health England. Chapter 6 Contraindications and Special Considerations. Immunisation against infectious 
disease (the Green Book). Last updated October 2017. www.gov.uk/government/publications/contraindications-
and-special-considerations-the-green-book-chapter-6    
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to the Medicines and Healthcare Products Regulatory Agency (MHRA) using 
the Yellow Card scheme. 
 
Risk of anaphylaxis following administration of LAIV 
As with all vaccines, there is a very rare possibility of this vaccine causing a 
severe allergic reaction (anaphylaxis). All healthcare professionals 
responsible for vaccination should be trained to recognise and treat 
anaphylaxis. 
 
Which vaccine to give a pregnant girl 
There is limited data on the use of live attenuated flu vaccine in pregnancy. 
While there is no evidence of risk with LAIV, inactivated flu vaccines are 
preferred for those who are pregnant. There is no need, however, to 
specifically test eligible girls for pregnancy or to advise avoidance of 
pregnancy in those who have been recently vaccinated. There are no specific 
precautions regarding pregnant women who are exposed to children who 
have been vaccinated with LAIV as the likelihood of onward tranmsission is 
considered very low.  
 
Egg allergy 
JCVI has advised4 that children with an egg allergy – including those with 
previous anaphylaxis to egg – can be safely vaccinated with LAIV in any 
setting (including primary care and schools). The only exception is for children 
who have required admission to intensive care for a previous severe 
anaphylaxis to egg, for whom no data are available; such children are best 
given LAIV in the hospital setting. LAIV remains the preferred vaccine for this 
group and the intranasal route is less likely to cause systemic reactions. 
 
Children with egg allergy but who also have another condition which 
contraindicates LAIV (eg immunosuppression) should be offered an 
inactivated influenza vaccine with a very low ovalbumin content (less than 
0.12 micrograms/ml). If these children are aged under nine years and have 
not previously been vaccinated against influenza, they will require a second 
dose of vaccine four weeks after the first. 
 
Egg-allergic children with asthma can receive LAIV if their asthma is well 
controlled (please see the advice on asthma in the Precautions section 
above). 
                                            
 
4 Joint Committee on Vaccination and Immunisation Minutes of the February 2015 meeting. Available at : 
www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation#minutes   
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Inactivated vaccines with ovalbumin content more than 0.12µg/ml (equivalent 
to 0.06µg for 0.5ml dose) or where content is not stated should not be used in 
egg-allergic children. The ovalbumin content of the flu vaccines for 2019/20 is 
on the PHE Annual flu programme web page. 
 
Egg-allergic children aged nine years and over can be given the quadrivalent 
inactivated egg-free vaccine, Flucelvax Tetra, which is licensed for use in this 
age group. 
 
The use of inactivated flu vaccine when LAIV is contraindicated 
For children in clinical risk groups under 18 years of age where LAIV is 
contraindicated (or it is otherwise unsuitable), an appropriate quadrivalent 
inactivated influenza vaccine should be offered. For the 2019/20 flu season, 
PHE has purchased egg-grown quadrivalent influenza vaccine (QIVe) for 
these children which can be ordered through the ImmForm website: 
www.immform.dh.gov.uk 
 
Inactivated flu vaccines suitable for children are presented as prefilled 
syringes for intramuscular injection. The preferred site for injection is the 
anterolateral aspect of the thigh for infants under one year. Children over one 
year of age can receive the vaccine in the deltoid region of the upper arm. 
 
Some inactivated flu vaccines are restricted to use in particular age groups or 
are not suitable for those with an egg allergy. Those administering flu 
vaccines must be familiar with, and refer to the manufacturer’s SPC for 
individual brands when administering inactivated flu vaccines. 
 
Inactivated flu vaccines can cause similar systemic adverse reactions as 
LAIV. They may also cause injection site reactions (redness, swelling, 
tenderness). These usually disappear after one or two days. 
 
How many doses of inactivated flu vaccine to give 
Where a child, aged two years to less than nine years, cannot receive LAIV 
due to a contraindication (or other reason) and has not received any flu 
vaccine before, they should receive two doses of inactivated flu vaccine, with 
the second dose at least four weeks after the first. The inactivated flu 
vaccines are interchangeable – the second dose does not have to be the 
same vaccine given for the first dose. This also applies to children aged 6 
months to two years who are too young to be eligible for LAIV. 
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Children who have received one or more doses of any flu vaccine before 
should be considered as previously vaccinated. Two doses are only required 
the first year the child receives any flu vaccine. In subsequent years, they can 
be given a single dose as their immune system will already have been 
primed. 
 
Deferring vaccination due to acute illness 
If the child has an acute severe febrile illness, LAIV administration should be 
deferred until recovered. Minor illnesses without fever or systemic upset are 
not valid reasons to postpone vaccination. 
 
Vaccine constituents 
The LAIV is supplied in a single use nasal applicator (type 1 glass) with 
nozzle (polypropylene with polyethylene transfer valve), nozzle tip-protector 
(synthetic rubber), plunger rod, plunger stopper (butyl rubber) and dose 
divider clip, none of which should affect latex sensitive individuals. 
 
LAIV does not contain any preservatives such as thiomersal but it does 
contain a highly processed form of gelatine (derived from pigs) as one of its 
additives. Gelatine is commonly used in a range of pharmaceutical products, 
including many capsules and some vaccines. The gelatine in LAIV is used as 
a stabiliser - it protects the live viruses from the effects of temperature.  
 
The gelatine used in live vaccines is highly purified and hydrolysed (broken 
down by water), so it is different from the natural gelatine used in foods. Very 
sensitive scientific tests have shown that no DNA from pigs can be detected 
in the LAIV nasal flu vaccine (Fluenz Tetra). These tests show that the 
gelatine is broken down so much that the original source cannot be 
identified5. 
 
Vaccine acceptability for Muslim and Jewish communities 
Members of Muslim or Jewish religious communities may be concerned about 
using vaccines that contain gelatine from pigs (porcine gelatine). This 
statement from representatives of the Jewish community may help some 
patients/parents/carers to reach a decision about having the vaccine:  
 
                                            
 
5 Oxford Vaccine Group. Vaccine Knowledge Project Vaccine ingredients page, gelatine section. Available at: 
vk.ovg.ox.ac.uk/vaccine-ingredients#gelatine  
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Rabbi Abraham Adler from the Kashrus and Medicines Information Service 
said:  
“It should be noted that according to Jewish laws, there is no problem with 
porcine or other animal derived ingredients in non-oral products. This includes 
vaccines, including those administered via the nose, injections, suppositories, 
creams and ointments”. 
 
However, it is acknowledged that some groups within the British Muslim 
community may consider the porcine product to be forbidden. The final 
decision about whether parents have their child vaccinated is with them. In 
order to come to an informed decision, they should be able to consider the 
evidence about the advantages and disadvantages of the vaccination. They 
may wish to seek advice from their faith leaders or other community leaders. 
 
Fluenz Tetra is the only live attenuated flu vaccine available in Europe.  
 
Current policy is that only those who are in clinical risk groups are able to 
receive an inactivated injectable vaccine as an alternative. Children who are 
not in clinical risk groups should only be offered LAIV. A child who is unable 
to have LAIV, for reasons other than being medically contraindicated, will 
continue to derive benefit from the programme by virtue of the reduction of 
transmission among their peers. They are not eligible for an inactivated 
vaccine. 
 
PHE’s statement6 on vaccines and gelatine can be found here. PHE has also 
published a specific document7: Children’s flu vaccination programme, the 
nasal flu vaccine and porcine gelatine. 
 
Ordering, storage and handling 
Ordering LAIV 
All flu vaccines for children are purchased centrally by PHE. This includes 
vaccine for all children aged two to three years, for children in reception class 
and school years 1 to  6 and for children in risk groups aged six months to 
less than 18 years.  
 
                                            
 
6 Public Health England (2014) Vaccines and Gelatin: PHE’s response. www.gov.uk/government/news/vaccines-
and-gelatine-phe-response   
7 Public Health England (2014). The children’s flu vaccination programme, the nasal flu vaccine Fluenz and 
porcine gelatine. www.gov.uk/government/publications/childrens-flu-vaccination-programme-nasal-flu-vaccine-
and-porcine-gelatine    
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For children in risk groups under 18 years of age where LAIV is 
contraindicated, a suitable quadrivalent inactivated influenza vaccine has 
been procured centrally by PHE. The quadrivalent inactivated influenza 
vaccine being supplied by PHE is licensed for children from six months of 
age.  
 
LAIV and inactivated injectable flu vaccines for children can be ordered 
through the ImmForm website: www.immform.dh.gov.uk as for other centrally 
purchased vaccines.  
 
It is important not to order or hold more than two weeks worth of LAIV; local 
stockpiling can cause delays in stock being released and increases the risk of 
significant loss if there are cold chain failures. It also increases the risk of out 
of date vaccine being used as Fluenz Tetra has a short shelf life. 
 
In previous flu seasons, ordering controls using allocations based on previous 
years uptake were introduced on centrally supplied flu vaccines. These were 
put in place to reduce the amount of excess vaccine, in particular LAIV, 
ordered by providers but not administered to children. Ordering controls will 
also be in place in 2019/20. Further information on ordering controls and 
other ordering advice for LAIV will be available in Vaccine Update and on the 
ImmForm news item both prior to, and during, the flu vaccination period.  
 
Storing LAIV 
LAIV must be stored in accordance with the manufacturer’s instructions. It 
should be stored between +2°C and +8°C in its original packaging and 
protected from light. It must not be frozen and as for other vaccines, heat 
speeds up the decline in potency, reducing vaccine shelf life. 
 
Before use, LAIV may be out of the refrigerator for a maximum period of 12 
hours at a temperature not above 25°C as indicated in the Summary of 
Product Characteristics2 (SPC). If the vaccine has not been used after this 12 
hour period, it should be disposed of.  
 
Shelf life of LAIV 
LAIV has an expiry date 18 weeks after manufacture – this is much shorter 
than inactivated injectable flu vaccines. Expiry dates should be checked 
regularly and all efforts should be made to vaccinate children before the 
Christmas holidays if possible. 
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Vaccine safety and efficacy 
Potential side-effects of LAIV  
Nasal congestion/runny nose (rhinorrhoea), reduced appetite, malaise and 
headache are common adverse reactions following administration of LAIV. 
Hypersensitivity reactions such as urticaria, facial oedema, bronchospasm 
and anaphylaxis can occur rarely. 
 
LAIV efficacy 
LAIV provides good overall protection for children against influenza virus, and 
is expected to provide some cross-protection against mismatched strains. 
Using a live attenuated vaccine provides more antigenic stimuli; more 
elements of the immune system are involved resulting in the production of IgA 
(important in mucosal immunity), a T-cell response and cell mediated 
immunity. Vaccine effectiveness varies from year to year depending upon the 
circulating strains and the vaccine composition. The overall adjusted vaccine 
effectiveness for 2018/19 for 2 to 17 year olds receiving LAIV was 48.6%. 
 
In August 2016, JCVI reviewed all the UK and other international evidence in 
light of emerging evidence of low effectiveness of the nasal spray vaccine 
(lower than inactivated vaccine), reported in the United States (US). After 
reviewing evidence from across the UK, Finland, Canada and the US 
following the 2015/16 influenza season, much of which demonstrates good 
overall effectiveness, the clear recommendation of the JCVI was to continue 
to recommend the use of the live attenuated influenza nasal spray vaccine for 
preventing flu in children and the continuation of the UK childhood influenza 
immunisation programme together with on-going intensive monitoring of the 
programme performance. 
 
For more information please go to: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file
/548515/JCVI_statement.pdf 
 
Timing of vaccination 
Vaccination should be given in sufficient time to ensure children are protected 
before flu starts circulating. If an eligible child presents late for vaccination it is 
generally appropriate to still offer it however and this is particularly important if 
it is a late flu season. The decision to vaccinate should take into account the 
fact that the immune response to vaccination takes about two weeks to fully 
develop.  
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As the immunisation teams have to go into a considerable number of schools 
in a short space of time, some children may be offered immunisation later in 
the season. Parents of any child at risk from flu because of an underlying 
medical condition can choose to receive flu vaccination in general practice, 
especially if the parent does not want their child to have to wait for the school 
vaccination session. GP practices should invite these children for vaccination, 
making it clear to their parents that they have the option to have their child 
vaccinated in general practice.  
 
Vaccine administration 
Administering LAIV 
LAIV is administered by the intranasal route and is supplied in an applicator 
that allows 0.1ml to be administered into each nostril (total dose of 0.2ml). 
Clear diagrams showing administration are provided in the SPC and NHS 
Education for Scotland has made a video for health professionals on how to 
administer the vaccine.  
 
Administration of LAIV by healthcare staff in clinical risk groups  
In theory, healthcare workers may have low level exposure to live attenuated 
influenza vaccine viruses during administration of the vaccine and/or from 
recently vaccinated patients. The vaccine viruses are cold-adapted and 
attenuated however and are unlikely to cause symptomatic influenza. In the 
US, where there has been extensive use of LAIV, no transmission of vaccine 
virus in healthcare settings has ever been reported and there have been no 
reported instances of illness or infections from the vaccine virus among 
healthcare professionals inadvertently exposed. Thus, the US Centers for 
Disease Control and Prevention has considered that the risk of acquiring 
vaccine viruses from the environment is unknown but is probably low8. As a 
precaution, however, very severely immunosuppressed individuals should not 
administer LAIV. Other healthcare workers who have less severe 
immunosuppression or are pregnant, should take reasonable precautions to 
avoid inhaling the vaccine and ensure that they themselves are appropriately 
vaccinated. 
 
                                            
 
8 Centers for Disease Control and Prevention (2013) Prevention and Control of Seasonal Influenza with Vaccines: 
Recommendations of the Advisory Committee on Immunization Practices — United States, 2013–2014. MMWR 
September 20, 62(RR07);1-43 
www.cdc.gov/mmwr/preview/mmwrhtml/rr6207a1.htm?s_cid=rr6207a1_w#AvailableLAIV    
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Sneezing, nose blowing and nasal dripping following administration  
If the child sneezes, blows their nose or has nasal dripping following 
administration of LAIV, the vaccine dose does not need to be repeated. 
Binding of the virus to epithelial cells occurs very rapidly and there are more 
virus particles in the vaccine than are needed to establish immunity. 
Therefore sneezing or blowing the nose immediately after immunisation with 
LAIV will not affect immunity9 and reassurance should be given that the 
vaccine will still be effective if any of these occur.  
 
Administering LAIV when the patient has a blocked or runny nose 
There are no data on the effectiveness of LAIV when given to children with a 
heavily blocked or runny nose (rhinitis) caused by infection or allergy. As 
heavy nasal congestion might impede delivery of the vaccine to the 
nasopharyngeal mucosa, deferral of administration until resolution of the 
nasal congestion or use of an appropriate alternative intramuscularly 
administered inactivated flu vaccine should be considered. 
 
Administering an incomplete dose of vaccine  
It is not necessary to repeat the dose of vaccine as long as at least 0.1ml of 
the vaccine has been given intranasally10 as each half dose (0.1ml) contains 
enough viral particles to induce an immune response11. 
 
If the vaccine is accidentally squirted into the child’s eye, it may cause some 
slight irritation to the eye and eyewash/normal saline should be used to wash 
out the eye. The child/parent should be advised to seek medical advice if any 
irritation occurs and persists beyond what might reasonably be expected.  
 
 
                                            
 
9 Astra Zeneca. Re: FLUMIST (influenza vaccine [live attenuated]) – Re-administration of FLUMIST subsequent to 
sneezing [Internet] Message to: British Columbia Centre for Disease Control. 2013 July 30. Cited in: British 
Columbia Centre for Disease Control  Live Attenuated Influenza Vaccine Questions and Answers for Health Care 
Providers 2013-2014 . Revised Nov 2013 
10 Astra Zeneca. FLUMIST® (Influenza Vaccine [Live, attenuated]) – Inadvertent Oral Administration & 
Inadvertent Eye Exposure [Internet] Message to: British Columbia Centre for Disease Control. 2013 July 30. Cited 
in: British Columbia Centre for Disease Control  Live Attenuated Influenza Vaccine Questions and Answers for 
Health Care Providers 2013-2014. Revised Nov 2013 
11 Astra Zeneca. FLUMIST® (Influenza Vaccine [Live, attenuated]) – Single nostril Administration/Inadvertent 
Single Nostril Administration [Internet] Message to: British Columbia Centre for Disease Control. 2013 July 30. 
Cited in: British Columbia Centre for Disease Control  Live Attenuated Influenza Vaccine Questions and Answers 
for Health Care Providers 2013-2014 . Revised Nov 2013 
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What to do if the child refuses the second half of the vaccine dose after the 
first half has been given 
As each half dose (0.1ml) contains enough viral particles to induce an 
immune response11, it is not necessary to offer an inactivated vaccine or a 
repeat live vaccine on another occasion. 
 
Inadvertent administration of both half doses in the same nostril 
It is recommended that LAIV be administered as two divided sprays (0.1ml 
into each nostril) to maximise the vaccine’s contact surface area of epithelial 
cells within the nasopharynx. No clinical trials have been conducted using a 
single-nostril administration. However, there is no need to repeat 
immunisation as each half dose (0.1ml) contains enough viral particles to 
induce an immune response11. 
 
Inadvertent administration of LAIV to a child who is aged less than 24 months 
LAIV is contraindicated in children aged less than 24 months due to an 
increase in adverse events in this age group. An increase in wheezing and 
hospitalisation was observed in clinical trials that included children aged from 
six to 23 months of age. The decision not to license the vaccine for use in 
children aged less than 24 months was based on these observations rather 
than vaccine efficacy in this age group.  
 
Children who have received LAIV at less than 24 months of age do not 
require a replacement dose. The inadvertently administered vaccine should 
count as a valid dose as LAIV will provide protection in this age group. 
However, the child’s parents/carers should be informed of the possible 
adverse events in the short term and advised to seek medical care if adverse 
events occur. They should be reassured that no long term effects from 
receiving LAIV are anticipated. 
 
Children from six months of age in clinical risk groups who have not received 
a flu vaccine previously should count the inadvertently administered LAIV as 
the first dose. The child should also be offered the inactivated flu vaccine four 
weeks later to complete the two dose schedule (in line with the 
recommendation that children aged six months to under 9 years who have not 
received inactivated flu vaccine previously should be offered a second dose 
at least four weeks after the first dose). If the child reaches their second 
birthday in the four weeks between the dose of LAIV and when a second 
dose of flu vaccine would be due, a further dose of LAIV can be given (if not 
contraindicated). 
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Healthcare professionals should report the administration error via their local 
governance system(s) so that lessons can be learnt and the risk of future 
errors minimised.  
 
Inadvertent administration of LAIV to a child who is immunosuppressed 
If an immunocompromised individual receives LAIV then the degree of 
immunosuppression should be assessed. If the individual is severely 
immunocompromised, antiviral prophylaxis should be considered. Otherwise 
they should be advised to seek medical advice if they develop flu-like 
symptoms in the four days (the usual incubation period) following 
administration of the vaccine. If antivirals are used for prophylaxis or 
treatment, then in order to maximise their protection in the forthcoming flu 
season, the patient should also be offered inactivated influenza vaccine. This 
can be given straight away. 
 
Healthcare professionals should report the administration error via their local 
governance system(s) so that the appropriate action can be taken, lessons 
can be learned and the risk of future errors minimised. 
 
Recognition of severe immunosuppression 
An individual may be considered severely immunosuppressed if they: 
 
• are severely immunodeficient due to conditions or immunosuppressive 
therapy 
• have acute and chronic leukaemia 
• have lymphoma 
• are HIV positive and not on highly active antiretroviral therapy 
• have a cellular immune deficiency 
• are taking a high dose of steroids 
 
Administering LAIV with other vaccines 
LAIV can be given at the same time as, or at any interval before or after other 
vaccines, including live vaccines. Although it was previously recommended 
that, where vaccines cannot be administered simultaneously, a four-week 
interval should be observed between live viral vaccines, JCVI has now 
advised that no specific intervals need to be observed between the live 
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attenuated intranasal flu vaccine and other live vaccines. See ‘Intervals 
between vaccines” section in Green Book Chapter 1112 for more information. 
 
Administering LAIV with antiviral agents against flu 
There is a potential for flu antiviral agents to lower the effectiveness of LAIV. 
Therefore, flu antiviral agents and LAIV should not be administered 
concomitantly. LAIV should be delayed for at least 48 hours after cessation of 
treatment with flu antiviral agents. Administration of flu antiviral agents within 
two weeks of administration of LAIV may adversely affect the effectiveness of 
the vaccine. 
 
Inadvertent administration of an expired dose of LAIV  
Inadvertently administering an expired dose of LAIV is unlikely to cause harm 
to the child other than that the expired dose may not offer them adequate 
protection. Health professionals should inform the parent/carer of the error, 
provide reassurance where necessary and discount the expired dose. An 
additional dose of LAIV that is in date should be offered as soon as possible 
(on the same day as the expired vaccine was given or as soon as the error is 
discovered), to ensure satisfactory protection. There is no minimum interval 
between an expired and a valid dose of LAIV as it is the same product being 
administered. In the event that ‘in date’ LAIV is not available, a suitable 
inactivated flu vaccine should be offered as an alternative.  
 
Inadvertently administering an expired dose of LAIV is a clinical incident that 
should be reported via the local governance system(s), so that appropriate 
action can be taken, lessons can be learnt and the risk of future errors 
minimised.  
 
Administering LAIV to patients with a needle phobia  
Patients aged 18 years and older with a needle phobia, should be 
encouraged, where possible, to have the injected inactivated vaccine.  
 
LAIV is not licensed in adults because there is some evidence of poorer 
efficacy when compared with the inactivated vaccine. 
 
                                            
 
12 Public Health England. Chapter 11 The UK Immunisation Schedule.Immunisation against infection disease 
(the Green Book). Revised April 2019. Available at: www.gov.uk/government/publications/immunisation-
schedule-the-green-book-chapter-11  
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However, individual medical practitioners may choose to use LAIV  ‘off-label’ 
for adults, without any other medical contraindication, who are eligible for 
influenza vaccination but who cannot be vaccinated with injectable vaccines. 
This could include patients with learning difficulties who become seriously 
distressed with needles.  
 
The legislation does allow for such situations and the Medicines and 
Healthcare products Regulatory Agency state that ‘there are clinical situations 
when…the use of medicines outside the terms of the licence (ie, ‘off-label’) 
may be judged by the prescriber to be in the best interest of the patient on the 
basis of available evidence’13. The responsibility for such use rests with the 
health professional. In this situation, a patient specific direction (PSD) will be 
required. In these exceptional circumstances, where it has not proved 
possible to administer the inactivated vaccine, PHE has agreed that the 
national LAIV stock can be used for this purpose.  
  
                                            
 
13 Medicines and Healthcare products Regulatory Agency. Off-label or unlicensed use of medicines: 
prescribers’ responsibilities. Available on Gov.uk website at: www.gov.uk/drug-safety-update/off-label-or-
unlicensed-use-of-medicines-prescribers-responsibilities  
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Useful links 
Letter detailing 2019/20 flu programme 
Department of Health and Social Care, Public Health England, NHS England. 
The national flu immunisation programme 2019/20. Published 22 March 2019. 
Available at: www.gov.uk/government/publications/national-flu-immunisation-
programme-plan 
 
Immunisation against infectious disease (the Green Book) Influenza 
chapter 19. Available at: www.gov.uk/government/publications/influenza-the-
green-book-chapter-19 
 
Leaflets, posters and training slides prepared specifically for the childhood 
flu programme. Available at: www.gov.uk/government/collections/annual-flu-
programme  
 
Flu posters, leaflets and schools guidance can be ordered from: 
The DH health and social care website 
https://www.orderline.dh.gov.uk/ecom_dh/public/saleproducts.jsf 
 
Toolkit for childhood flu programme available at: 
www.gov.uk/government/publications/flu-immunisation-toolkit-for-programme-
extension-to-children 
 
A video for health professionals on how to administer LAIV produced by 
NHS Education for Scotland is available at:  
www.nes.scot.nhs.uk/education-and-training/by-theme-initiative/public-
health/health-protection/seasonal-flu/childhood-seasonal-flu-vaccination-
programme-resources-for-registered-practitioners.aspx 
 
Fluenz Tetra® Summary of Product Characteristics and Patient 
Information Leaflet available at: www.medicines.org.uk/emc/product/3296  
 
PGD templates for LAIV and inactivated flu vaccines are available at: 
www.gov.uk/government/collections/immunisation-patient-group-direction-pgd  
 
Additional flu resources available at: 
www.gov.uk/government/collections/annual-flu-programme  
